

ENDOOnline2020 PROGRAM GUIDE

JUNE 8-22, 2020 ENDOONLINE.ENDOCRINE.ORG



ENDOOnline2020 THANK YOU TO OUR SUPPORTERS

THE ENDOCRINE SOCIETY IS PROUD TO PARTNER WITH PEERS AND INDUSTRY TO ADVANCE EXCELLENCE AND PROMOTE SCIENTIFIC DISCOVERY, MEDICAL PRACTICE, AND HUMAN HEALTH.





















ENDO ONLINE 2020 SUPPORTERS AS OF JUNE 1, 2020.

ENDOOnline2020 THANK YOU TO OUR PARTNER SOCIETIES

WHO HAVE OFFERED THEIR ENDORSEMENT AND HELPED TO PROMOTE THIS OPPORTUNITY TO THE ENDOCRINE COMMUNITY.








































ENDO ONLINE 2020 PARTNER SOCIETIES AS OF MAY 20, 2020.



TABLE OF CONTENTS

- 2 GENERAL INFORMATION
- 4 LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 8-12
- 9 BASIC SCIENCE DAY: JUNE 8
- 13 LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 15-19
- 15 ON-DEMAND SESSIONS
- 19 25TH ANNIVERSARY OF DIVERSITY AND INCLUSION
- 20 AWARD AND LAUREATE RECIPIENTS
- 21 PRODUCT THEATERS AND EXHIBIT HALL VIEWING



GENERAL INFORMATION

We are excited to offer ENDO Online 2020, our largest-ever virtual meeting for endocrine researchers and clinicians. This complimentary event will take place June 8-22, and will feature a comprehensive mixture of on-demand and live programming, offering attendees the opportunity to learn about the latest developments in hormone science and medicine from renowned investigators, expert clinicians, and educators from all over the world.

ENDO Online 2020 includes:

- an easy-to-navigate online Conference Center;
- on-demand sessions focused on a variety of clinical topics, including pituitary, diabetes, and more;
- live programming dedicated to basic science;
- availability to earn Continuing Medical Education credits and Maintenance of Certification points;
- programming for early career professionals; and
- a digital exhibit hall where participants can access resources and chat with exhibitors about the latest science and technology.

CONTINUING MEDICAL EDUCATION AND MAINTENANCE OF CERTIFICATION

The Endocrine Society designates this educational activity for a maximum of 23.75 AMA PRA Category 1 Credit(s)™ for ENDO Online 2020. Physicians should claim only the credit commensurate with extent of their participation in the activity.

These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

In addition, ENDO Online 2020 credit, each ancillary symposium will provide 1.5 *AMA PRA Category 1 Credits(s)*TM and the 2020 Endocrine Fellows Series: Type 1 Diabetes Care and Management course will provide 10.25 *AMA PRA Category 1 Credits(s)*TM.

ENDO 2021

ENDO is the place where leading experts, researchers, and the most respected clinicians in the field come together to share the latest findings in hormone science and discuss breakthroughs in clinical care. We are excited to host ENDO 2021 at the San Diego Convention Center in San Diego, CA, USA, on March 20–23, 2021. For additional information, visit endocrine.org/ENDO2021.

CLINICAL ENDOCRINOLOGY UPDATE (CEU) 2020 AND ENDOCRINE BOARD REVIEW (EBR) 2020

Given the global recommendations for social distancing, these historically live courses will transition to live online courses in 2020. We look forward to delivering the premier content that makes CEU and EBR so valuable. For updates, please visit endocrine.org/CEU2020 and endocrine.org/EBR2020.



CME Credits: **1.5** AMA PRA Category

1 Credits™ and **1.5** ABIM MOC Points

IMPROVING OUTGOMES IN ACROMEGALY- Let Your Patients Be Your Guide

Monday, June 8, 2020 12:00 рм – 1:30 рм EDT

AGENDA

12:00 PM Introduction and Pretest

Adriana loachimescu, MD, PhD

12:10 PM Acromegaly Pathophysiology

and Personalized Measures

of Manifestations

Shlomo Melmed, MD

12:30 PM Acromegaly: Current

and Emerging

Treatment Paradigms

Lisa Nachtigall, MD

12:55 PM Clinical Cases

Moderated by

Adriana loachimescu, MD, PhD

1:15 PM Posttest and

Question & Answer

1:30 PM Conclusion

ACTIVITY CHAIR



Adriana loachimescu, MD, PhD

Professor of Medicine (Endocrinology) and Neurosurgery Emory University School of Medicine Co-Director, Emory Pituitary Center Atlanta. GA

FACULTY



Shlomo Melmed, MD

Executive Vice President and Dean Cedars-Sinai Medical Center Los Angeles, CA



Lisa Nachtigall, MD

Clinical Director

Neuroendocrine and Pituitary Clinical Center

Massachusetts General Hospital

Associate Professor Department of Medicine Harvard Medical School

Boston, MA

REGISTRATION

To register for ENDO Online 2020 and/or add an <u>Ancillary program</u> to your existing ENDO Online 2020 registration, visit the ENDO registration page.





LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 8-12

USE THE SCHEDULE PROVIDED BELOW TO ORGANIZE THE SESSIONS YOU WILL ATTEND DURING ENDO ONLINE 2020.

| MONDAY, JUNE 8 | | |
|----------------|----------------|--|
| | 10:00-10:05 AM | WELCOME E. Dale Abel, MD, PhD, Immediate Past President, Endocrine Society |
| | 10:05–11:00 AM | THE IMPACT OF COVID-19 ON ENDOCRINOLOGY 1.0 AMA PRA Category 1 Credits™ Chairs: Andrea Giustina, MD and John Newell-Price, MD, PhD, FRCP Impact of Diabetes/Obesity on Adverse Outcomes from COVID-19 Manuel Puig-Domingo, MD, PhD Practical Management of Diabetes in Patients with COVID-19 Daniel J. Drucker, MD Clinical Guidance for Patients with Adrenal Insufficiency During COVID-19 Pandemic |
| | | Wiebke Arlt, MD, DSc, FRCP, FMedSci Panel Discussion with Faculty Drs. Arlt, Drucker, Guistina, Newell-Price, and Puig-Domingo |
| | 12:00-1:30 PM | IMPROVING OUTCOMES IN ACROMEGALY: LET PATIENTS BE YOUR GUIDE 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points Supported by Chiasma, Inc. Managed by Vindico Medical Education Chair: Adriana loachimescu, MD, PhD Acromegaly Pathophysiology and Personalized Measures of Manifestations Shlomo Melmed, MD Acromegaly: Current and Emerging Treatment Paradigms Lisa Nachtigall, MD Clinical Cases Adriana loachimescu, MD, PhD |

TUESDAY, JUNE 9: BASIC SCIENCE DAY

| Ш | 10:00-11:00 AM | BASIC MECHANISMS IN REPRODUCTION: FROM BEGINNING TO END |
|---|----------------|---|
| | | |

1.0 AMA PRA Category 1 Credits™

Chair: Genevieve Scott Neal-Perry, PhD, MD

Regulation of Mouse Uterine Contractility by Regulator of G-Protein Signalling 2

Daniela Urrego, BHSc

Kisspeptin as a Biomarker for Pregnancy Complications

Maria Phylactou, MBBS

Ovarian Follicle Survival Is Determined by Follicle-Stimulating Hormone Receptor (FSHR)

and Estrogen Receptor (GPER) Heteromers

Livio Casarini, PhD

The Expression of the Homeodomain Transcription Factor SIX3 within Kisspeptin

Neurons Is Necessary for Reproduction in Mice

Shanna Newton Lavalle, BS

| | 11:00 AM-12:00 PM | THE MANY FACES OF DIABETES, OBESITY, AND METABOLISM 1.0 AMA PRA Category 1 Credits™ Chair: Kevin Y Lee, PhD | | |
|--|-------------------|--|--|--|
| | | Circadian Regulation of Chromatin State Mediates Pancreatic Islet Incretin Response Benjamin John Weidemann, BS | | |
| | | Hepatocyte Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Offsets the Anti-Steatogenic Effects of Thiazolidinediones in Obese Male Mice Jose T Muratalla, Biochemistry Undergrad | | |
| | | The Transcriptional Coactivation Function of EHMT2 Restricts Chronic Glucocorticoid Exposure Induced Insulin Resistance Rebecca Arwyn Lee, MS | | |
| | | Epinephrine Is Essential for Normal Renal Glucose Reabsorption via the Glucose Transporter GLUT2 Arwa Mahmoud Elsheikh, MBBS | | |
| | 12:00-1:00 PM | KEYNOTE: IF WE KNEW THEN WHAT WE KNOW NOW, WOULD WE HAVE APPROACHED THE DEVELOPMENT OF ENDOCRINE THERAPIES DIFFERENTLY 1.0 AMA PRA Category 1 Credits™ | | |
| | | Keynote Presenter: Donald P. McDonnell, PhD Moderator: Stephen R. Hammes, MD, PhD | | |
| | 1:00-2:00 PM | THE MANY FACES OF NUCLEAR RECEPTOR BIOLOGY 1.0 AMA PRA Category 1 Credits™ | | |
| | | Chair: Zeynep Madak-Erdogan, PhD | | |
| | | Kruppel-Like Factors 9 and 13 Cooperate to Maintain Mammalian Neuronal Differentiation Jose Avila-Mendoza, PhD | | |
| | | Expression of SLC35F1 in the Plasma Membrane of Cells of Aldosterone Producing Cell Clusters (APCCs) and Its Possible Role in Aldosterone Synthesis Emily Goodchild, BMBS, BSc | | |
| | | Nuclear Receptor CAR Protects Female Mice from the Development of Diet-Induced Nonalcoholic Fatty Liver Disease | | |
| | | Fabiana Oliviero, Masters Degree When the Glucocorticoid Receptor Meets the Mineralocorticoid Receptor in the Nucleus of Human Cells Maria G. Petrillo, PhD | | |
| | 2:00-3:00 PM | FROM THE BRAIN TO THE BELLY—INSIGHTS INTO PITUITARY AND ADRENAL PHYSIOLOGY | | |
| | | 1.0 AMA PRA Category 1 Credits™ | | |
| | | Chair: Lori Therese Raetzman, PhD | | |
| | | OTX2 Mutations in Congenital Hypopituitarism Patients | | |
| | | Louise Cheryl Gregory, PhD Single-Cell Sequencing Identifies Novel Regulators of Thyrotrope Populations and | | |
| | | POU1F1-Independent Thyroid-Stimulating Hormone Expression Leonard Cheung, PhD | | |
| | | Glucocorticoid Production in the Nervous and Immune Systems: Evidence for a Local HPA Axis Homolog Melody Salehzadeh, BSc | | |
| | | Sepsis-Induced Critical Illness in Mice Alters Key Regulators of ACTH Production and Secretion Within the Anterior Pituitary Gland Arno Téblick, MD | | |



WEDNESDAY, JUNE 10, 2020 12:00-1:30 PM EDT

PROGRAM CHAIR



Steven Edelman, MD Professor of Medicine University of California, San Diego Veterans Affairs Medical Center Solana Beach, CA

FACULTY



Jeremy Pettus, MD Assistant Professor of Medicine University of California, San Diego San Diego, CA



Rayhan A. Lal, MD Stanford University Medical Center Sunnyvale, CA

This activity is supported by an educational grant from Abbott Diabetes Care, Medtronic, and Novo Nordisk, Inc.

LEARNING OBJECTIVES

Upon completing this activity, learners will be able to:

- Better understand risks related to hypoglycemia
- Decrease the frequency and severity of hypoglycemia as an ADE among patients with T2D on insulin and/or SUs who are identified as high risk
- Discuss the role of currently available pipeline methods to lower hypoglycemia risk

AGENDA

Welcome and Introduction

Steven Edelman, MD

Setting the Stage: The Science Behind Time in Range

Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD


Method to the Madness: How to Integrate Time in Range into Your Practice Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD

Case Workshop

Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD

CME Credits: 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points





THURSDAY, JUNE 11, 2020 12:00-1:30 PM EDT

PROGRAM CHAIR



W. Timothy Garvey, MD
Department Chair of
Nutrition Science
University of Alabama
Birmingham, AL

FACULTY



Sangeeta R. Kashyap, MD Assistant Professor of Medicine Cleveland Clinic Foundation Cleveland, Ohio



Lisa Neff, MD Assistant Professor of Medicine Northwestern University Chicago, IL

LEARNING OBJECTIVES

Upon completing this activity, learners will be able to:

- Review and identify the available and emerging therapeutic approaches to obesity
- Know what's new in the obesity medicine pipeline
- Review different approaches to weight loss/maintenance

AGENDA

Welcome and Introduction W. Timothy Garvey, MD

Life Cycle of a Patient with Obesity Case Scenarios Featuring a Standardized Patient On:

Lifestyle TherapyMedical TherapySurgeryLisa Neff, MDW. Timothy Garvey, MDSangeeta R. Kashyap, MD

Roundtable Discussion and Closing All Faculty

CME Credits: 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points

This activity is supported by an educational grant from Novo Nordisk, Inc.



| 10:00 AM-12:00 PM | EXHIBIT HALL HOURS |
|-------------------|--|
| 12:00–1:30 PM | BREAKING BAD: REDUCING GLUCOSE VARIABILITY AND INCREASING TIME IN RANGE IN PATIENTS WITH DIABETES |
| | 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points |
| | Supported by Novo Nordisk, Inc., Abbott Diabetes Care, Medtronic |
| | Chair: Steven Edelman, MD |
| | Setting the Stage: The Science Behind Time in Range Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD |
| | Method to the Madness: How to Integrate Time in Range into Your Practice |
| | Steven Edelman, MD; Jeremy Pettus, MD; Rayhan A. Lal, MD |
| THURSDAY, JUNI | E 11 |
| 10:00 AM-12:00 PM | EXHIBIT HALL HOURS |
| 12:00–1:30 PM | BREAKING THE CYCLE: APPROACHES TO LONG-TERM WEIGHT LOSS AND OBESITY CARE |
| | 1.0 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points |
| | Supported by Novo Nordisk, Inc. |
| | Chair: W. Timothy Garvey, MD |
| | Life Cycle of a Patient with Obesity Case Scenarios Featuring a |
| | Standardized Patient On: Lifestyle Therapy Lisa Neff, MD |
| | Life Cycle of a Patient with Obesity Case Scenarios Featuring a |
| | Standardized Patient On: Medical Therapy W. Timothy Garvey, MD |
| | Life Cycle of a Patient with Obesity Case Scenarios Featuring a Standardized Patient On: Surgery Sangeeta R. Kashyap, MD |
| FRIDAY, JUNE 12 | |
| <u> </u> | |
| 10:00 AM-12:00 PM | EXHIBIT HALL HOURS |
| 1:00-1:45 PM | WHAT'S NEW WITH ABIM'S MAINTENANCE OF CERTIFICATION? |
| | 0.75 AMA PRA Category 1 Credits™ Presenter: Susan J. Mandel, MD, MPH |
| | reserver. Odsario. Mandel, MD, MI 11 |



□ 10:00-11:00 AM

BASIC MECHANISMS IN REPRODUCTION: FROM BEGINNING TO END

1.0 AMA PRA Category 1 Credits™

Chair: Genevieve Scott Neal-Perry, PhD, MD

Regulation of Mouse Uterine Contractility by Regulator of G-Protein Signalling 2

Daniela Urrego, BHSc

Kisspeptin as a Biomarker for Pregnancy Complications

Maria Phylactou, MBBS

Ovarian Follicle Survival Is Determined by Follicle-Stimulating Hormone Receptor (FSHR)

and Estrogen Receptor (GPER) Heteromers

Livio Casarini, PhD

The Expression of the Homeodomain Transcription Factor SIX3 within Kisspeptin

Neurons Is Necessary for Reproduction in Mice

Shanna Newton Lavalle, BS

□ 11:00 AM-12:00 PM

THE MANY FACES OF DIABETES, OBESITY, AND METABOLISM 1.0 AMA PRA Category 1 Credits™

Chair: Kevin Y Lee, PhD

Circadian Regulation of Chromatin State Mediates Pancreatic Islet Incretin Response Benjamin John Weidemann, BS

Hepatocyte Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Offsets the Anti-Steatogenic Effects of Thiazolidinediones in Obese Male Mice

Jose T Muratalla, Biochemistry Undergrad

The Transcriptional Coactivation Function of EHMT2 Restricts Chronic Glucocorticoid Exposure Induced Insulin Resistance

Rebecca Arwyn Lee, MS

Epinephrine Is Essential for Normal Renal Glucose Reabsorption via the Glucose Transporter GLUT2

Arwa Mahmoud Elsheikh, MBBS

□ 12:00-1:00 PM

KEYNOTE: IF WE KNEW THEN WHAT WE KNOW NOW, WOULD WE HAVE APPROACHED THE DEVELOPMENT OF ENDOCRINE THERAPIES DIFFERENTLY

1.0 AMA PRA Category 1 Credits™

Keynote Presenter: Donald P. McDonnell, PhD Moderator: Stephen R. Hammes, MD, PhD



1:00-2:00 PM

THE MANY FACES OF NUCLEAR RECEPTOR BIOLOGY

1.0 AMA PRA Category 1 Credits™

Chair: Zeynep Madak-Erdogan, PhD

Kruppel-Like Factors 9 and 13 Cooperate to Maintain Mammalian Neuronal Differentiation

Jose Avila-Mendoza, PhD

Expression of SLC35F1 in the Plasma Membrane of Cells of Aldosterone Producing Cell Clusters (APCCs) and Its Possible Role in Aldosterone Synthesis

Emily Goodchild, BMBS, BSc

Nuclear Receptor CAR Protects Female Mice from the Development of Diet-Induced Nonalcoholic Fatty Liver Disease

Fabiana Oliviero, Master's Degree

When the Glucocorticoid Receptor Meets the Mineralocorticoid Receptor in the Nucleus of Human Cells

Maria G. Petrillo, PhD

П 2:00-3:00 PM

FROM THE BRAIN TO THE BELLY-INSIGHTS INTO PITUITARY AND ADRENAL PHYSIOLOGY

1.0 AMA PRA Category 1 Credits™

Chair: Lori Therese Raetzman, PhD

OTX2 Mutations in Congenital Hypopituitarism Patients

Louise Cheryl Gregory, PhD

Single-Cell Sequencing Identifies Novel Regulators of Thyrotrope Populations and POU1F1-Independent Thyroid-Stimulating Hormone Expression

Leonard Cheung, PhD

Glucocorticoid Production in the Nervous and Immune Systems: Evidence for a Local **HPA Axis Homolog**

Melody Salehzadeh, BSc

Sepsis-Induced Critical Illness in Mice Alters Key Regulators of ACTH Production and Secretion Within the Anterior Pituitary Gland

Arno Téblick, MD



BLAZING AHEAD

WITH ADVANCES IN THE MANAGEMENT OF ADULT GROWTH HORMONE DISORDER



MONDAY, JUNE 15, 2020 12:00 — 1:30 PM EST Symposium

ACTIVITY OVERVIEW AND FORMAT

This highly engaging and interactive live symposium will answer participant questions regarding the management of patients with adult growth hormone disorder (aGHD). Faculty will participate in a combination of didactic presentations and roundtable discussions to address currently relevant topics regarding the treatment of aGHD. In addition, the audience will be able to ask questions based on their personal level of knowledge and clinical experience, and these questions will be addressed immediately and thoroughly from multiple expert viewpoints.

INTENDED AUDIENCE

This activity is intended for endocrinologists and endocrinology healthcare providers who diagnose and manage aGHD.

LEARNING OBJECTIVES

Upon completing this activity, learners will be able to:

- Identify aGHD based on presenting disease features and results of appropriate diagnostic tests
- Assess characteristics of current and emerging aGHD treatment options to identify optimal individualized regimens based on patients' clinical and personal characteristics
- Describe available standard-of-care and emerging therapeutic approaches to address challenges of aGHD management, such as timely treatment initiation, treatment adherence, and therapeutic monitoring
- Discuss disease management challenges associated with transitioning pediatric patients with GHD to adulthood

PROGRAM AGENDA

12:00 - 12:10 PM **Program Introduction and Preactivity Assessment**

12:10 - 12:25 PM How Does aGHD Present and How Should the Diagnosis Be Confirmed?

12:25 - 12:45 PM What Are the Treatment Options for Adults With GHD and the Consequences of Remaining Untreated?

What Techniques Can Provide Solutions to the Challenges of Treating aGHD? 12:45 - 1:05 PM

1:05 - 1:25 PM What Are the Unique aGHD Management Challenges as Pediatric Patients With GHD Transition

to Adulthood?

1:25 - 1:30 PM **Postactivity Assessment and Closing**

FACULTY

MARK E MOLITCH, MD-PROGRAM CHAIR

Northwestern University Feinberg School of Medicine Chicago, Illinois

DAVID R CLEMMONS, MD

University of North Carolina Chapel Hill, North Carolina

JULIE SILVERSTEIN. MD

Medical Director Pituitary Center Associate Professor of Medicine and Neurological Surgery Division Endocrinology, Metabolism and Lipid Research Washington University School of Medicine St Louis, Missouri

REGISTRATION

There is no cost to participate in this symposium. Register for ENDO Online 2020 here. Add an Ancillary Symposium to your existing registration here.

CME CREDITS: 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points







WEDNESDAY, JUNE 17, 2020 12:00-1:30 PM EDT

PROGRAM CHAIR



Michael T. McDermott Professor of Medicine University of Colorado Hospital Aurora, CO

FACULTY



Elizabeth Seaquist, MDProfessor of Medicine
University of Minnesota
Minneapolis, MN



Cecilia Low Wang, MD
Professor of Medicine
University of Colorado
Anschutz Medical Campus,
Denver. CO

CME Credits: 1.5 AMA PRA Category
1 Credits™ and 1.5 ABIM MOC Points

This activity is supported by an educational grant from Lilly USA, LLC.

LEARNING OBJECTIVES

Upon completing this activity, learners will be able to:

- Better understand risks related to hypoglycemia
- Decrease the frequency and severity of hypoglycemia as an ADE among patients with T2D on insulin and/or Sus who are identified as high risk
- Discuss the role of currently available pipeline methods to lower hypoglycemia risk

AGENDA

Welcome and Introduction

Lack of Hypoglycemia Awareness in Insulin and Sulfonylurea-Using Diabetics Michael McDermott, MD

Review of Endocrine Society's Prevention Initiative and Discussion of Management Strategies and Current Pipeline Methods to Lower Severe Hypoglycemia Michael McDermott, MD

Master Clinician Discussions:

- Hypoglycemia Considerations and Management in Patients with CAD and CKD Elizabeth Seaquist, MD
- New Treatment Options for Severe Hypoglycemia Cecilia Low Wang, MD
- Severe Hypoglycemia Patient on Continuous Glucose Monitoring Michael McDermott, MD


Roundtable Discussion and Closing All Faculty



LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 15–19

USE THE SCHEDULE PROVIDED BELOW TO ORGANIZE THE SESSIONS YOU WILL ATTEND DURING ENDO ONLINE 2020.

| MONDAY, JUNE 1 | 15 |
|-------------------|--|
| 10:00 AM-12:00 PM | EXHIBIT HALL HOURS |
| 12:00-1:30 PM | BLAZING AHEAD WITH ADVANCES IN THE MANAGEMENT OF ADULT GROWTH HORMONE DISORDER 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points Supported by Novo Nordisk, Inc. Managed by Institute for Medical and Nursing Education Chair: Mark E Molitch, MD Speakers: David R Clemmons, MD and Julie Silverstein, MD How Does aGHD Present and How Should the Diagnosis Be Confirmed? What are the Treatment Options for Adults with GHD and the Consequences of Remaining Untreated? What Techniques Can Provide Solutions to the Challenges of Treating aGHD? What are the Unique aGHD Management Challenges as Pediatric Patients with GHD Transition to Adulthood? |
| TUESDAY, JUNE | 16 |
| 10:00 AM-12:00 PM | EXHIBIT HALL HOURS |
| 12:00-1:00 PM | WHAT ELSE YOU SHOULD KNOW ABOUT RESILIENCY, COMMUNICATIONS, COLLABORATIONS, AND TEACHING STRATEGIES: A LIVE QUESTION AND ANSWER SESSION WITH FACULTY 1.0 AMA PRA Category 1 Credits™ |
| WEDNESDAY, JU | NE 17 |
| 10:00 AM-12:00 PM | EXHIBIT HALL HOURS |
| 12:00-1:30 PM | SEVERE HYPOGLYCEMIA: THE FREQUENTLY FORGOTTEN THREAT 1.5 AMA PRA Category 1 Credits™ and 1.5 ABIM MOC Points Supported by Lilly USA, LLC Chair: Michael McDermott, MD Lack of Hypoglycemia Awareness in Insulin and Sulfonylurea-Using Diabetics Michael McDermott, MD Review of Endocrine Society's Prevention Initiative and Discussion of Management Strategies and Current Pipeline Methods to Lower Severe Hypoglycemia Michael McDermott, MD Master Clinician Discussions: Hypoglycemia Considerations and Management in Patients with CAD and CKD Elizabeth Seaquist, MD New Treatment Options for Severe Hypoglycemia Cecilia Low Wang, MD Severe Hypoglycemia Patient on Continuous Glucose Monitoring Michael McDermott, MD |



LIVE AND ANCILLARY SYMPOSIA SESSIONS: JUNE 15-19 (CONTINUED)

| THURSDAY, JUN | IE 18 |
|----------------|---|
| 12:00-1:00 PM | TYPE ONE DIABETES FELLOWS CONFERENCE QUESTIONS AND ANSWERS WITH THE FACULTY 1.0 AMA PRA Category 1 Credits™ |
| 1:00-1:30 PM | DEVICE DEMONSTRATION BY ABBOTT DIABETES CARE, INC. |
| 1:30-2:00 PM | DEVICE DEMONSTRATION BY INSULET CORPORATION |
| FRIDAY, JUNE 1 | 9 |
| 12:00-12:30 PM | DEVICE DEMONSTRATION BY MEDTRONIC DIABETES |
| 12:30-1:00 PM | DEVICE DEMONSTRATION BY DEXCOM, INC. |
| 1:00-1:30 PM | DEVICE DEMONSTRATION BY TANDEM DIABETES CARE, INC. |

ON-DEMAND SESSIONS

ON-DEMAND SESSIONS WILL BE AVAILABLE FOR YOU TO VIEW AT YOUR CONVENIENCE STARTING ON MONDAY, JUNE 8 AT 11:00 AM FOLLOWING OUR OPENING SESSION, THE IMPACT OF COVID-19 ON ENDOCRINOLOGY.

PROFESSIONAL DEVELOPMENT SESSIONS

□ EFFECTIVE TEACHING STRATEGIES

1.0 AMA PRA Category 1 Credits™

Nuha A. El Sayed, MD, MM Sc Mark S. Roberson, PhD

☐ MANAGING COMMUNICATION CHALLENGES IN SCIENCE

1.0 AMA PRA Category 1 Credits™

Sally Camper , PhD Cecilia Low Wang, MD Peter Trainer, MD

☐ RESILIENCY AND MANAGING BURNOUT

1.0 AMA PRA Category 1 Credits™

Stanley Andrisse, PhD
Deborah T. Rana, MSc, MD, FAAP
Stuart Slavin, MD, Med

☐ TRANSCENDING BOUNDARIES: HOW TO EFFECTIVELY BUILD GLOBAL NETWORKS AND PARTNERSHIPS

1.0 AMA PRA Category 1 Credits™

Diana Cruz Topete, PhD Ana Claudia Latronico, MD, PhD

MEET THE PROFESSOR CLINICAL SESSIONS

☐ CONTROVERSIES IN BARIATRIC SURGERY

0.75 AMA PRA Category 1 Credits™

Jenny Tong MD, MPH Marzieh Salehi, MD

☐ HEALTHCARE OF THE TRANSWOMAN ACROSS THE LIFESPAN

0.75 AMA PRA Category 1 Credits™

Vin Tangpricha MD, PhD

☐ MODERATE TO SEVERE ACTIVE THYROID EYE DISEASE

0.75 AMA PRA Category 1 Credits™

Chrysoula Dosiou, MD Andrea Kossler, MD

□ PHARMACOTHERAPY IN OBESITY

0.75 AMA PRA Category 1 Credits™

Marc-Andre Cornier, MD David Saxon, MD, MSc

□ TYPE 1 DIABETES MELLITUS: FROM PRECONCEPTION TO POSTPARTUM

0.75 AMA PRA Category 1 Credits™

Elizabeth Buschur, MD

EDUCATIONAL SESSIONS

BREAKING BARRIERS TO CARE

1.0 AMA PRA Category 1 Credits™

Increasing Patient Participation in Research: Strategies for Success

James R. Gavin, PhD, MD

П

Reconsidering Race in the Estimation of Kidney Function

Nwamaka D. Eneanya, MD, MPH

□ 2020 ENDOCRINE FELLOWS SERIES: TYPE 1 DIABETES CARE AND MANAGEMENT*

10.0 AMA PRA Category 1 Credits™ and 10.0 ABIM MOC Points

A Fresh Look at Insulin Therapy

Challenging Cases in the Diagnosis of T1D

Practical Considerations and Approaches to Data Management

Irl B. Hirsch, MD

Developmental Considerations For Youth with T1D and Their Families

Jill Weissberg-Benchell, PhD, CDE

Exercise Management: Considerations and Strategies for T1D

Michael Riddell, PhD

Hypoglycemia in T1D: Risks and Practical Prevention Strategies

Elizabeth Rachel Seaguist, MD

Identifying and Confronting Challenging Transitions

Linda M. Siminerio, RN, PhD, CDE

Implementing Realistic Nutrition Strategies

Alison Evert, MS, RD, CDE

Insights into Insulin Pump Therapy

The Endocrinologist's Role in Screening/Managing Microvascular Disease

Janet B. McGill, MD

Interpreting CGM with Your Patients

Davida F. Kruger, Masters

Managing the Sick Patient at Home

Optimizing Multiple Daily Injection Therapy

Jenise Colleen Wong, MD, PhD

Time in Range: The Power of Partnership

Kelly Close, MBA

Going Beyond Injected Insulin: Emerging Options for T1D

David M. Harlan, MD. UMass Memorial Medical Center

T1D and the Prevention and Treatment of Macrovascular Disease

Robert H. Eckel, MD, University of Colorado

What I Wish I was Told When I Left my Fellowship

Luisa Duran, MD, John Muir Health

*This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc.; Dexcom, Inc.; Helmsley Charitable Trust; Insulet Corporation; Lilly USA, LLC; Medtronic Diabetes; Novo Nordisk, Inc.; and Tandem Diabetes Care.

*Please Note: The evaluation content is available on the Endocrine Society Center for Learning at education.endocrine.org.

☐ TELEMEDICINE IN THE AGE OF COVID-19

1.0 AMA PRA Category 1 Credits™

Developed in collaboration with the European Society of Endocrinology

Chairs: Gary D. Hammer, MD and Martin Reincke, MD

Perspectives on Rare Endocrine Conditions

Alberto M. Pereira Arias, MD, PhD

Lessons Learned from Virtual Tumor Boards

Sophie Leboulleux, MD

New Use of Home Lab Measurements for e-consults

Ravinder J. Singh, PhD

□ PRIMARY PREVENTION OF ASCVD AND T2DM IN PATIENTS AT METABOLIC RISK: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE

1.5 AMA PRA Category 1 Credits™

Moderator: Marie E. McDonnell, MD

Task Force Chair: James L. Rosenzweig, MD

Panelists:

Lars F. Berglund, MD, PhD Marie-France Hivert, MD Rita R. Kalyani, MD

THE YEAR IN PITUITARY: CLINICAL AND RESEARCH BREAKTHROUGHS

0.75 AMA PRA Category 1 Credits™

Mirjam Christ-Crain, MD, PhD

JDRF: TYPE 1 DIABETES - LOOKING INTO THE FUTURE

1.5 AMA PRA Category 1 Credits™

Chair: Sanjoy Dutta, PhD

Cures 1: Endogenous Approach - Combining Beta Cell Regenerative and Immunotherapeutic Approaches for T1D

Carla Joy Greenbaum, MD

Cures 2: Exogenous Approach - Cell (Beta) Replacement Therapy for T1D

Bernhard Hering, MD

Innovations in Treatments: Device- and Drug-Based Approaches for Management of T1D

Lori M. Laffel, MD, MPH

CLINICAL TRIAL ABSTRACT PRESENTATIONS

□ ADRENAL MEDICINE – CLINICAL APPLICATIONS AND NEW THERAPIES

0.5 AMA PRA Category 1 Credits™

A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia Deborah P. Merke, MS, MD

The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study Richard Joseph Auchus, MD, PhD

□ CHALLENGES IN REPRODUCTIVE ENDOCRINOLOGY: LATE BREAKING INSIGHTS

0.25 AMA PRA Category 1 Credits™

Using Kisspeptin to Predict Pubertal Outcomes for Youth With Pubertal Delay

Yee-Ming Chan, MD, PhD

□ CLINICAL CHALLENGES IN DIABETES AND METABOLISM

0.75 AMA PRA Category 1 Credits™

Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)

Juan Pablo Frias, MD

Leptin Decreases De Novo Lipogenesis in Lipodystrophic Patients

Annah Petek Baykal, BS

Racial Differences in Technology Use Among Type 1 Diabetes in a Safety-Net Hospital

Kathryn Fantasia, MD

☐ MECHANISMS AND TREATMENT OF OBESITY IN HUMANS

0.25 AMA PRA Category 1 Credits™

Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial Aaron S. Kelly, PhD



ON-DEMAND SESSIONS (CONTINUED)

□ NEW FRONTIERS IN BONE AND MINERAL METABOLISM

1.0 AMA PRA Category 1 Credits™

Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome Thomas O. Carpenter, MD

Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial Farzana Perwad, MD

Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis

Robert A. Feldman, MD

Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss Anne Sophie Sølling, MD

☐ THYROID AUTOIMMUNITY AND BENIGN THYROID DISEASE

0.25 AMA PRA Category 1 Credits™

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)

Lori J. Wirth, MD

□ UNDERSTANDING PEDIATRIC GROWTH DISORDERS

0.5 AMA PRA Category 1 Credits™

Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency

Aristides K. Maniatis, MD

Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial

Cheri L. Deal, MD, PhD



CELEBRATING 25 YEARS OF DIVERSITY IN ENDOCRINOLOGY

FOLLOW OUR JOURNEY TO CREATING A MORE DIVERSE AND INCLUSIVE GLOBAL ENDOCRINE COMMUNITY THROUGH THESE *ENDOCRINE NEWS* ARTICLES IN THE ENDO ONLINE 2020 RESOURCE CENTER:

A QUARTER CENTURY CELEBRATING DIVERSITY

A RAINBOW COALITION: LGBTQ+ OUTREACH

EXPANDING HORIZONS: A LOOK AT THE ENDOCRINE SOCIETY'S EVOLVING MINORITY

OUTREACH

EMBRACING AUTHENTICITY: CELEBRATING 25 YEARS OF DIVERSITY AND INCLUSION



2020 LAUREATE AWARDS

FRED CONRAD KOCH LIFETIME ACHIEVEMENT AWARD

Presented to Richard J. Santen, MD

SIDNEY H. INGBAR AWARD FOR DISTINGUISHED SERVICE

Presented to Carol A. Lange, PhD

INTERNATIONAL EXCELLENCE IN ENDOCRINOLOGY AWARD

Presented to Roy Shires, MBBCh, PhD, FRCP

OUTSTANDING CLINICAL INVESTIGATOR AWARD

Presented to Greet H. Van den Berghe, MD, PhD

OUTSTANDING LEADERSHIP IN ENDOCRINOLOGY AWARD

Presented to John C. Marshall, MD, PhD

VIGERSKY OUTSTANDING CLINICAL PRACTITIONER AWARD

Presented to Peter A. Singer, MD

OUTSTANDING EDUCATOR AWARD

Presented to Alvin C. Powers, MD

RICHARD E. WEITZMAN OUTSTANDING EARLY CAREER INVESTIGATOR AWARD

Presented to Andrew N. Dauber, MD

OUTSTANDING MENTOR AWARD

Presented to Ashely Grossman, MD, FRCP

THE JOHN D. BAXTER PRIZE FOR ENTREPRENEURSHIP

Presented to Daniel J. Drucker, MD

GERALD D. AURBACH AWARD FOR OUTSTANDING TRANSLATIONAL RESEARCH

Presented to Donald P. McDonnell, PhD

OUTSTANDING INNOVATION AWARD

Presented to Christopher B. Newgard, PhD

OUTSTANDING SCHOLARLY PHYSICIAN AWARD

Presented to R. Michael Tuttle, MD

ROY O. GREEP AWARD FOR OUTSTANDING RESEARCH

Presented to Eleftheria Maratos-Flier, MD

PRODUCT THEATERS AND EXHIBIT HALL VIEWING

Product Theater Presentations and Exhibits offer ENDO Online 2020 learners additional educational opportunities. A number of companies will provide a 30-minute focused presentation on the latest products available on the market that clinicians and advanced practice professionals that can impact your practice. Additionally, through the virtual exhibit hall that you can continue your educational journey to learn more about products that can make a difference to your patients.

Thank you to this year's exhibitors:

PRODUCT THEATERS

NP THYROID® (THYROID TABLETS, USP): UNDERSTANDING THE OPTIONS FOR MANAGEMENT OF HYPOTHYROIDISM

Sponsored by Acella Pharmaceuticals

Presenter:

Gary M. Pepper, MD

Palm Beach Diabetes & Endocrine Specialists Palm Beach, FL

For the majority of patients seeking treatment for hypothyroidism and Hashimoto's thyroiditis, levothyroxine (LT4) monotherapy is the recommended first line treatment. However, many patients remain symptomatic despite achieving normal lab values and thyroid function tests. There is a growing body of clinical evidence that suggests certain subsets of patients with hypothyroidism, such as those with genetic polymorphisms of the D2 deiodinase gene, may benefit from combination therapy with both T4 and T3. This product theater will provide a synopsis of the management of hypothyroidism with combination therapy as well as an overview of NP Thyroid, which is a natural desiccated porcine thyroid extract containing both T4 and T3 indicated for thyroid hormone replacement in hypothyroidism and Hashimoto's thyroiditis.

THE NEXT GENERATION OF THE GUARDIAN™ CONNECT CONTINUOUS GLUCOSE MONITORING SYSTEM: ACCURACY WHEN IT MATTERS MOST WITH REAL WORLD OUTCOMES

Sponsored by Medtronic

Presenter:

Bruce Bode, MD

Introduction to the new Guardian™ Connect CGM app, featuring even more customizable prediction, easier onboarding, and new CareLink™ reports for your practice. Please join us to learn more about the system and the different measures of accuracy, with real world outcomes and case studies demonstrating the integration of CareLink™ reports to help you manage your patients on multiple daily injections.

A PARADIGM SHIFT FOR THE MANAGEMENT OF THYROID EYE DISEASE (TED)

Sponsored by Horizon Therapeutics

Presenters:

Raymond S. Douglas, MD, PhD

Professor of Ophthalmology Director, Orbital and Thyroid Eye Disease Center Cedars-Sinai Medical Center, Los Angeles, CA

Terry J. Smith, MD

Frederick G.L. Huetwell

Professor of Ophthalmology and Visual Sciences Professor, Department of Internal Medicine Kellogg Eye Center

University of Michigan Medical School, Ann Arbor, MI

Come learn about the importance of early identification and a new treatment approach for Thyroid Eye Disease (TED) management. This presentation is intended for US-based healthcare professionals.

ENABLING TELEMEDICINE AND REMOTE MONITORING WITH THE FREESTYLE LIBRE 14 DAY SYSTEM

This program is sponsored by Abbott, the speaker or speakers are presenting on behalf of Abbott and the content of the program is in compliance with applicable regulatory requirements.

Presenter:

Daniel Einhorn, MD, FACP, FACE

Medical Director, Scripps Whittier Diabetes Institute Clinical Professor of Medicine, University of California, San Diego President, Diabetes and Endocrine Associates


Join us to learn about the #1 CGM worldwide[†] used by more than 2 million people*, the FreeStyle Libre 14 day system.

Daniel Einhorn, MD, FACP, FACE will share how he utilizes the FreeStyle Libre 14 day system to enable diabetes management and monitoring of patients remotely. He will also share real-world telemedicine patient cases.

Disclaimers

[†]Data based on the number of users worldwide for FreeStyle Libre personal CGM compared to the number of users for other leading personal CGM brands.

*Data based on the number of users worldwide for FreeStyle Libre products. In the United States product is branded FreeStyle Libre 14 day System.



PRODUCT THEATERS AND EXHIBIT HALL VIEWING (CONTINUED)

CLINICAL MANAGEMENT OF ADRENOCORTICAL CARCINOMA (ACC)

Sponsored by HRA Pharma Rare Diseases

Presenter:

Mouhammed Amir Habra, MD, FACP, FACE

Associate Professor, Deptartment of Endocrine Neoplasia and Hormonal Disorders

MD Anderson Cancer Center, Houston, TX

Adrenocortical Carcinoma (ACC) is a rare endocrine tumor with a poor prognosis that requires a multi-disciplinary approach between endocrinologists, oncologists and surgeons. The presentation will focus on the diagnosis, prognosis and current treatment guidelines for ACC patients.

PRECISION MEDICINE IN SKELETAL DYSPLASIAS: GENETICS, PATHOPHYSIOLOGY, & INVESTIGATIONAL APPROACHES TO THERAPY

Sponsored by BioMarin Pharmaceuticals

Chair and Presenter:

Ron Rosenfeld, MD

Pediatric Endocrinologist
Professor and Chair (emeritus) of Pediatrics
Oregon Health and Science University

Presenters:

Julie Hoover-Fong, MD, PhD

Clinical Geneticist

Greenberg Center for Skeletal Dysplasias McKusick-Nathans Department of Genetic Medicine Johns Hopkins University, Baltimore, MD

Nadia Merchant, MD

Pediatric Endocrinologist & Clinical Geneticist Children's National Hospital, Washington, DC

Bradley S. Miller, MD, PhD

Professor

Division of Endocrinology

Department of Pediatrics

University of Minnesota Masonic Children's Hospital, Minneapolis, MN

More than 400 skeletal dysplasias have a genetic basis of disease identified. Currently, these patients may experience lifelong, progressive, multisystemic comorbidities. This ondemand presentation, moderated by Dr. Ron Rosenfeld, brings together 4 experts who will discuss the genetic basis of skeletal dysplasias, their pathophysiology, and the development of investigational therapies for achondroplasia.

FINALLY, AN ORAL TESTOSTERONE REPLACEMENT THERAPY FOR MEN WITH HYPOGONADISM

Sponsored by Clarus Therapeutics


Presenter:

Paresh Dandona MD, PhD

State University of New York at Buffalo, Buffalo, New York

Join us for an overview of an FDA-approved and available oral testosterone replacement therapy. During this program, an expert will discuss the history and challenges of TRTs, and the pathway to approval for this oral option, as well as its safety and efficacy profiles.

Product Theater presentations are not part of ENDO Online 2020 official educational programming as planned by the Endocrine Society Program Committee. These events are neither sponsored nor endorsed by the Endocrine Society. These events do not qualify for continuing medical education (CME) credit.



PRODUCT THEATERS AND EXHIBIT HALL VIEWING (CONTINUED)

EXHIBITORS

Λ

Abbott Diabetes Care

Acella Pharmaceuticals

Amarin Pharma

Amgen

Amneal Pharmaceuticals, Inc.

Ascendis Pharma Inc.

AstraZeneca

В

BioMarin Pharmaceutical

Brain Recovery Project: Childhood Epilepsy Surgery Foundation

C

Clarus Therapeutics, Inc.

CoachCare

Crinetics Pharmaceuticals

D

Dexcom Inc.

Ē

EKF Diagnostics

н

Horizon Therapeutics

HRA Pharma

Immunovant, Inc.

Insulet Corporation

IPSEN Biopharmaceuticals, Inc.

M

Medtronic

N

National Adrenal Diseases Foundation

Norland at Swissray

Novo Nordisk Diabetes Care

Novo Nordisk Healthcare AG

P

Pfizer Inc.

Progenics

R

Roche Diabetes Care, Inc.

Ŧ

Takeda Pharmaceutical Company Limited

U

Ultragenyx Pharmaceutical, Inc. - Commercial Booth

Ultragenyx Pharmaceuticals, Inc. - Medical Booth





www.endohighlights2020.com

HIGHLIGHTS OF ENDOON in e2020

INCLUDING PRESENTATIONS SCHEDULED FOR ENDO 2020

FOCUS ON DIABETES & COMORBIDITIES

AVAILABLE IN 4 LANGUAGES!











SCAN THE CODE WITH YOUR SMARTPHONE

www.endohighlights2020.com:

- Video introduction
- International faculty interviews
 - Virtual meeting presentations
- Expert overview on the latest scientific information presented
 - ENDO 2020 conference summaries from key oral presentations
 - Podcasts from poster sessions
 - Downloadable slide kit

Keep up with the latest advances in diabetology & endocrinology care from the convenience of your home and office!

Visit www.endohighlights2020.com!

THIS PROGRAM IS DEVELOPED BY THE ENDOCRINE SOCIETY IN COLLABORATION WITH INFOMEDICA AND SUPPORTED

BY AN INDEPENDENT EDUCATIONAL GRANT PROVIDED BY NOVO NORDISK A/S. THE NATURE OF THE PROGRAM IS PURELY EDUCATIONAL AND NOVO NORDISK A/S HAS NO INFLUENCE IN THE CONTENT PRESENTED.





END 2021

SAVE THE DATE

MARCH 20-23, 2021 SAN DIEGO, CA, USA SAN DIEGO CONVENTION CENTER ENDOCRINE.ORG/ENDO2021



To get a preview of some of the research that was to be presented at ENDO, view the ENDO 2020 abstracts which are now available online in a supplemental issue of JES: bit.ly/ENDO2020Abstracts